Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
The CP-945,598 program was terminated on November 3, 2008 due to changing regulatory perspectives on the risk/benefit profile of the CB1 class and likely new regulatory requirements for approval. No safety issues were involved in the termination decision.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject must be overweight (BMI) \>/=30 kg/m2, for subjects without co morbidities; \>/=27 kg/m2 for subjects with co morbidities
Subjects who are willing and able to comply with 8 week Low Calorie Diet, scheduled visits, treatment plan, laboratory tests, and other trial procedures.
You may not be if
Participation in a formal weight loss program or significant weight loss (fluctuation \>5% of total body weight) in the past 3 months.
Subjects with serious medical or psychiatric conditions
Clareo Health | A 14-Month Study On The Effects Of CP-945,598 For The Prevention Of Weight Regain In Obese Patients
